RUNX1 and breast cancer

Mercado-Matos, Jose; Matthew-Onabanjo, Asia N.; Shaw, Leslie M.

doi:10.18632/oncotarget.17249

Cited by 17 publications

(13 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, upregulation of RUNX1 led to the increased expression of SOS1 and phosphorylation of ErbB2/HER2, subsequently promoting the proliferation of gastric cancer cells (Mitsuda et al, 2018). In the ER+ subtype of breast cancer, RUNX1 has been implicated as a tumour suppressor through the stabilization of Axis inhibition protein 1 (AXIN1) expression, but high RUNX1 expression correlates with poor prognosis in triple-negative breast cancers (Mercado-Matos, Matthew-Onabanjo & Shaw, 2017; Chimge et al, 2016). Additionally, loss of RUNX1 resulted in enhanced proliferation, migration, and invasion in lung cancer (Ramsey et al, 2018).…”

Section: Introductionmentioning

confidence: 99%

Increased expression of RUNX1 in clear cell renal cell carcinoma predicts poor prognosis

Sun

Man

et al. 2019

PeerJ

View full text Add to dashboard Cite

Background Runt-related transcription factor 1 (RUNX1) was previously reported to play a dual role in promoting or suppressing tumorigenesis in various malignancies. A public dataset from The Cancer Genome Atlas (TCGA) was used to evaluate the role of RUNX1 in clear cell renal cell carcinoma (ccRCC). Methods The Wilcoxon signed-rank test was used to compare the expression of RUNX1 in ccRCC tissues and normal tissues. The Wilcoxon signed-rank test and logistic regression were utilized to investigate the relationship between clinicopathological factors and RUNX1 expression. Additionally, we analysed the differences in prognosis between patients with high and low expression of RUNX1 via the Kaplan–Meier method and Cox regression. Gene set enrichment analysis (GSEA) was performed to explore the mechanisms of RUNX1 in ccRCC. Results The expression of RUNX1 in ccRCC tissues was significantly higher than that in normal tissues. High expression of RUNX1 was significantly associated with gender (p = 0.003), clinical stage (p < 0.001), tissue infiltration (p < 0.001), lymph node metastasis (p = 0.037) and histological grade (p < 0.001). Logistic regression analysis showed that high RUNX1 expression was significantly correlated with gender (OR = 1.71 for male vs. female, p = 0.004), histological grade (OR = 11.61 for grade IV vs. I, p < 0.001), clinical stage (OR = 1.55 for stage III/IV vs. I/II, p = 0.014) and tissue infiltration (OR = 1.54 for positive vs. negative, p = 0.018). Kaplan–Meier survival curves revealed that the prognosis of patients with ccRCC with high RUNX1 expression was worse than that of patients with ccRCC with low RUNX1 expression (p < 0.001). Univariate Cox regression analysis showed that high RUNX1 expression was strongly correlated with poor prognosis (HR = 1.60, 95% CI [1.31–1.97], p < 0.001). In addition, high expression of RUNX1 was an independent prognostic factor for poor overall survival (OS), with an HR of 1.50 (95% CI [1.20–1.87], p < 0.001) in multivariate Cox analysis. GSEA showed that the apoptosis, B cell receptor signalling pathway, calcium signalling pathway, chemokine signalling pathway, JAK/STAT signalling pathway, MAPK signalling pathway, p53 signalling pathway, pathways in cancer, T cell receptor signalling pathway, Toll-like receptor signalling pathway, VEGF signalling pathway, and Wnt signalling pathway were significantly enriched in the RUNX1 high-expression phenotype. In conclusion, RUNX1 can be used as a novel prognostic factor and therapeutic target in ccRCC.

show abstract

Section: Introductionmentioning

confidence: 99%

Increased expression of RUNX1 in clear cell renal cell carcinoma predicts poor prognosis

Sun

Man

et al. 2019

PeerJ

View full text Add to dashboard Cite

show abstract

“…RUNX1 is a transcription factor, known to be essential for the maturation of megakaryocytes [88]. It is known as a tumor suppressor in leukemia but has recently been implicated to have a role in other cancer types [89, 90]. A total of eleven regulators have their target lists enriched with this pathway in Metamatched, namely POGZ (20), ANKRD46 (17), RBBP5 (16), KMT2E (9), DAAM2 (4), LYL1 (3), ZNF446 (3), HOXD9 (2), NIPAL4 (2), HIST2H2BE (2) and RAB3A (2).…”

Section: Resultsmentioning

confidence: 99%

A meta-analysis of multiple matched aCGH/expression cancer datasets reveals regulatory relationships and pathway enrichment of potential oncogenes

Newton

Wernisch

2019

PLoS ONE

View full text Add to dashboard Cite

The copy numbers of genes in cancer samples are often highly disrupted and form a natural amplification/deletion experiment encompassing multiple genes. Matched array comparative genomics and transcriptomics datasets from such samples can be used to predict inter-chromosomal gene regulatory relationships. Previously we published the database METAMATCHED, comprising the results from such an analysis of a large number of publically available cancer datasets. Here we investigate genes in the database which are unusual in that their copy number exhibits consistent heterogeneous disruption in a high proportion of the cancer datasets. We assess the potential relevance of these genes to the pathology of the cancer samples, in light of their predicted regulatory relationships and enriched biological pathways. A network-based method was used to identify enriched pathways from the genes’ inferred targets. The analysis predicts both known and new regulator-target interactions and pathway memberships. We examine examples in detail, in particular the gene POGZ , which is disrupted in many of the cancer datasets and has an unusually large number of predicted targets, from which the network analysis predicts membership of cancer related pathways. The results suggest close involvement in known cancer pathways of genes exhibiting consistent heterogeneous copy number disruption. Further experimental work would clarify their relevance to tumor biology. The results of the analysis presented in the database METAMATCHED, and included here as an R archive file, constitute a large number of predicted regulatory relationships and pathway memberships which we anticipate will be useful in informing such experiments.

show abstract

“…The gene NRIP1 localized at 21q21 was described to be a susceptibility locus (Ghoussaini et al, 2012) and this region was among our identified CNVs. Also, other chromosome 21 regions were identified, containing genes as SAMSN1, associated with several cancer types such as multiple myeloma, lung cancer, glioblastoma, and RUNX1, implicated as an oncogene and tumor suppressor in breast cancer (Browne et al, 2015;Mercado-Matos, Matthew-Onabanjo, & Shaw, 2017;Noll et al, 2014;Yamada et al, 2008;Yan et al, 2013). Late disease stage was correlated to chromosome 19 copy number alterations.…”

Section: Discussionmentioning

confidence: 99%

Copy number alterations associated with clinical features in an underrepresented population with breast cancer

Peres

Carvalho

Anurag

et al. 2019

Molec Gen & Gen Med

View full text Add to dashboard Cite

Background As the most incident tumor among women worldwide, breast cancer is a heterogeneous disease. Tremendous efforts have been made to understand how tumor characteristics as histological type, molecular subtype, and tumor microenvironment collectively influence disease diagnosis to treatment, which impact outcomes. Differences between populations and environmental and cultural factors have impacts on the origin and evolution of the disease, as well as the therapeutic challenges that arise due to these factors. We, then, compared copy number variations (CNVs) in mucinous and nonmucinous luminal breast tumors from a Brazilian cohort to investigate major CNV imbalances in mucinous tumors versus non‐mucinous luminal tumors, taking into account their clinical and pathological features. Methods 48 breast tumor samples and 48 matched control blood samples from Brazilian women were assessed for CNVs by chromosome microarray. Logistic regression and random forest models were used in order to assess CNVs in chromosomal regions from tumors. Results CNVs that were identified in chromosomes 1, 5, 8, 17, 19, and 21 classify tumors according to their histological type, ethnicity, disease stage, and familial history. Conclusion Copy number alterations described in this study provide a better understanding of the landscape of genomic aberrations in mucinous breast cancers that are associated with clinical features.

show abstract

RUNX1 and breast cancer

Cited by 17 publications

References 8 publications

Increased expression of RUNX1 in clear cell renal cell carcinoma predicts poor prognosis

Increased expression of RUNX1 in clear cell renal cell carcinoma predicts poor prognosis

A meta-analysis of multiple matched aCGH/expression cancer datasets reveals regulatory relationships and pathway enrichment of potential oncogenes

Copy number alterations associated with clinical features in an underrepresented population with breast cancer

Contact Info

Product

Resources

About